
Teva terminates Ajovy at Phase 3 in episodic cluster headache
pharmafile | April 24, 2019 | News story | Research and Development | Teva, ajovy, headache, pharma
Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) in the treatment of episodic cluster headaches after it became apparent that the drug is unlikely to meet its primary endpoint at Phase 3.
Conclusions drawn from a pre-specified futility analysis of the Phase 3 ENFORCE study indicated that Ajovy would not adequately improve mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period, so the drugmaker has decided to discontinue the trial.
Despite the decision, Teva made clear that it would still pursue other applications of Ajovy, particularly in the treatment of post-traumatic headache, which is currently being evaluated at Phase 2.
“We’d like to thank the patients and investigators for their immense contributions to this study,” remarked Dr Tushar Shah, Senior Vice President, Head of Global Specialty Clinical Development at Teva. “Despite these results, we are continuing to evaluate if fremanezumab treatment can provide clinical benefits in additional diseases where anti-calcitonin gene-related peptide (CGRP) therapy may play a role in its pathophysiology.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …





